Pharmaceutical–academia deals have been stealing headlines this year, but more complex models of pharma–pharma collaboration are increasingly being seen as potential solutions to industry's most intractable challenges.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Partnering between pharma peers on the rise. Nat Rev Drug Discov 10, 561–562 (2011). https://doi.org/10.1038/nrd3526
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3526
This article is cited by
-
Pharmacogenomics in clinical practice and drug development
Nature Biotechnology (2012)